- Home
- RCAT vs CLLS Comparison
RCAT vs CLLS Comparison
Compare RCAT & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RCAT
- CLLS
- Stock Information
- Founded
- RCAT 2002
- CLLS 1999
- Country
- RCAT United States
- CLLS France
- Employees
- RCAT N/A
- CLLS N/A
- Industry
- RCAT Wholesale Distributors
- CLLS Biotechnology: Pharmaceutical Preparations
- Sector
- RCAT Industrials
- CLLS Health Care
- Exchange
- RCAT Nasdaq
- CLLS Nasdaq
- Market Cap
- RCAT 248.8M
- CLLS 240.2M
- IPO Year
- RCAT 2017
- CLLS 2007
- Fundamental
- Price
- RCAT $10.72
- CLLS $1.57
- Analyst Decision
- RCAT Strong Buy
- CLLS Buy
- Analyst Count
- RCAT 1
- CLLS 3
- Target Price
- RCAT $4.00
- CLLS $7.00
- AVG Volume (30 Days)
- RCAT 12.1M
- CLLS 59.8K
- Earning Date
- RCAT 12-16-2024
- CLLS 11-04-2024
- Dividend Yield
- RCAT N/A
- CLLS N/A
- EPS Growth
- RCAT N/A
- CLLS N/A
- EPS
- RCAT N/A
- CLLS N/A
- Revenue
- RCAT $16,468,647.00
- CLLS $36,042,000.00
- Revenue This Year
- RCAT $125.47
- CLLS $271.02
- Revenue Next Year
- RCAT $167.75
- CLLS $33.48
- P/E Ratio
- RCAT N/A
- CLLS N/A
- Revenue Growth
- RCAT 95.46
- CLLS 46.96
- 52 Week Low
- RCAT $0.56
- CLLS $1.53
- 52 Week High
- RCAT $12.57
- CLLS $3.55
- Technical
- Relative Strength Index (RSI)
- RCAT 59.10
- CLLS 27.91
- Support Level
- RCAT $7.76
- CLLS $1.85
- Resistance Level
- RCAT $9.99
- CLLS $2.09
- Average True Range (ATR)
- RCAT 1.35
- CLLS 0.09
- MACD
- RCAT -0.09
- CLLS -0.04
- Stochastic Oscillator
- RCAT 62.99
- CLLS 0.00
About RCAT Red Cat Holdings Inc.
Red Cat Holdings Inc is a military technology company that integrates robotic hardware and software to provide critical situational awareness and actionable intelligence to on-the-ground warfighters and battlefield commanders. Its mission is to enhance the effectiveness and safety of military operations domestically and globally. Red Cat's suite of solutions includes Teal Drones, developer of the Golden Eagle, a small unmanned system with the highest resolution imaging for night-time operations, and Skypersonic, a provider of unmanned aircraft for interior spaces and other dangerous environments.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC, product candidates in other therapeutic indications.